Testosterone metabolites in patients reduce the levels of very long chain fatty acids accumulated in X-adrenoleukodystrophic fibroblasts

Neuroscience Letters

Volumn 289, Issue 2, 2000, Pages 139-142

  Petroni, A ^a   Papini, N ^a   Blasevich, M ^a   Magnaghi, V ^a   Cavarretta, I ^a   Galli, C ^a   Melcangi, R C ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

3 Diol; 5 Androstan 17 ol 3 one; 5 Androstan 3 ,17 diol; Dihydrotestosterone; Testosterone; Very long chain fatty acids; X adrenoleukodystrophy

Indexed keywords

3BETA ANDROSTANEDIOL; ANDROSTANOLONE; TESTOSTERONE; VERY LONG CHAIN FATTY ACID;

ADRENOLEUKODYSTROPHY; ARTICLE; CASE REPORT; CONTROLLED STUDY; FIBROBLAST; HUMAN; HUMAN CELL; IN VITRO STUDY; LIPID METABOLISM; PRIORITY JOURNAL; SCHOOL CHILD; TESTOSTERONE METABOLISM;

ADRENOLEUKODYSTROPHY; CHILD; DIHYDROTESTOSTERONE; FATTY ACIDS; FIBROBLASTS; HUMANS; SKIN; TESTOSTERONE;

EID: 0033934566     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(00)01296-9     Document Type: Article

References (13)

1. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248-254.
2. Celotti F., Melcangi R.C., Martini L. The 5 alpha-reductase in the brain: molecular aspects and relation to brain function. Front. Neuroendocrinol. 13:1992;163-215.
3. Folch J., Lees M., Sloane Stanley G.H. A simple method for the isolation and purification of total lipids from animal tissues. J. Biol. Chem. 226:1957;497-509.
4. Igarashi M., Schaumburg H.H., Powers J., Kishimoto Y., Kolodny E., Suzuki K. Fatty acid abnormality in adrenoleukodystrophy. J. Neurochem. 26:1976;851-860.
5. Maris T., Androulidakis E.J., Tzagournissakis M., Papavassiliou S., Moser H., Plaitakis A. X-linked adrenoleukodystrophy presenting as neurologically pure familial spastic paraparesis. Neurology. 45:1994;1101-1104.
6. Melcangi R.C., Celotti F., Castano P., Martini L. Differential localization of the 5alpha-reductase and the 3alpha-hydroxysteroid dehydrogenase in neuronal and glial cultures. Endocrinology. 132:1993;1252-1259.
7. Melcangi R.C., Magnaghi V., Martini L. Steroid metabolism and effects in central and peripheral glial cells. J. Neurobiol. 40:1999;471-483.
8. Moser H.W., Borel J. Dietary management of X-linked adrenoleukodystrophy. Annu. Rev. Nutr. 15:1995;379-397.
9. Moser H. Adrenoleukodystrophy: phenotype, genetics, pathogenesis and therapy. Brain. 120:1997;1485-1508.
10. Petroni A., Bertagnolio B., La Spada P., Blasevich M., Papini N., Govoni S., Rimoldi M., Galli C. The β-oxidation of arachidonic acid and the synthesis of docosahexaenoic acid are selectively and consistently altered in skin fibroblasts from three Zellweger patients versus x-adrenoleukodystrophy, Alzheimer and control subjects. Neurosci. Lett. 250:1998;145-148.
11. Rizzo W.B., Leshner R.T., Odone A., Dammann A., Craft D.A. Dietary erucic acid therapy for X-linked adrenoleukodystrophy. Neurology. 39:1989;1415-1422.
12. Singh I., Moser A.B., Moser H.W., Kishimoto Y. Adrenoleukodystrophy: impaired oxidation of very long chain fatty acid s in white blood cells, cultured skin fibroblasts and amniocytes. Pediatr. Res. 18:1984;286-290.
13. Tsuji S., Ohno T., Miyatake T., Suzuki A., Yamakawa T. Fatty acid elongation activity in fibroblasts from patients with adrenoleukodystrophy (ALD). J. Biochem. 96:1984;1241-1247.